R
Rondo Therapeutics
Bispecific antibody therapies targeting solid tumors
About Rondo Therapeutics
Rondo Therapeutics, Inc. is a biopharmaceutical company founded in 2019 by Shelley Force Aldred, Ph.D. (CEO), and Nathan Trinklein, Ph.D. (President and CSO). The co-founders have a 20-year history of building successful companies together, including Teneobio, which was acquired by Amgen. Their experience at Teneobio, particularly in developing a CD3 T-cell engager platform, informs Rondo's mission to address the unmet need for effective cancer therapies for solid tumors.
The company develops a next-generation immuno-oncology platform focused on creating bispecific antibodies. This class of therapeutic is designed to engage the immune system to fight cancer. While bispecific antibodies have succeeded in treating hematologic (blood) cancers, applying this success to solid tumors has been a significant challenge. Rondo's proprietary approach involves designing antibodies with broad therapeutic windows that can activate and sustain a powerful anti-tumor response while sparing healthy tissue and minimizing toxic side effects. Their technology tunes the potencies of the immune-engaging arms and drives tumor localization to achieve efficacy without dose-limiting toxicities.
Rondo Therapeutics operates on a venture capital-backed business model. In March 2022, the company announced the closing of an oversubscribed $67 million Series A financing round. The round was co-led by Red Tree Venture Capital and Canaan Partners, with participation from Johnson & Johnson Innovation - JJDC, Inc., Novo Holdings A/S, and SV Health Investors. These funds are intended to advance Rondo's lead preclinical programs toward initial Phase 1 clinical studies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2022 | $67M | $268M | Johnson & Johnson Innovation · SV Health Investors · Canaan · Novo Holdings | ↗ |
Growth signals
Latest recorded traffic for Rondo Therapeutics is 2.8K monthly website visits, up 47.4% over the last three months. Rondo Therapeutics's team declined 9.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Rondo Therapeutics in the Hayward ecosystem
The Rondo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Canaan
Red Tree Venture Capital
Johnson & Johnson Innovation
SV Health Investors
Novo Holdings
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rondo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rondo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








